Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.3.1165

Malignant Transformation Rate and P53, and P16 Expression in Teratomatous Skin of Ovarian Mature Cystic Teratoma  

Zhu, Hai-Li (Department of Pathology, Nanfang Hospital, Southern Medical University)
Zou, Zhen-Ning (Department of Pathology, Nanfang Hospital, Southern Medical University)
Lin, Pei-Xin (Department of Pathology, Nanfang Hospital, Southern Medical University)
Li, Wen-Xia (Department of Pathology, Nanfang Hospital, Southern Medical University)
Huang, Ye-En (Department of Pathology, Nanfang Hospital, Southern Medical University)
Shi, Xiao-Xin (Department of Pathology, Nanfang Hospital, Southern Medical University)
Shen, Hong (Department of Pathology, Nanfang Hospital, Southern Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.3, 2015 , pp. 1165-1168 More about this Journal
Abstract
Objective: To investigate the incidence of malignant transformation and P53 and P16 expression in teratomatous skin of ovarian mature cystic teratoma. Materials and Methods: Data on ovarian teratoma specimens in nearly 10 years were reviewed. P53 and P16 expression were detected by immunohistochemistry in 25 cases of teratomatous skin of ovarian mature cystic teratoma, 20 cases of squamous cell carcinoma and 2 cases of squamous cell carcinoma originated from teratomatous skin. Results: Of 1913 cases of ovarian mature cystic teratoma in nearly 10 years, only two cases of squamous cell carcinoma were found in teratomatous skin, with malignant transformation rate of 0.1045%. P53 expression was detected in 2 cases squamous cell carcinoma originated from teratomatous skin and P16 overexpression in one. There were no expressions of P53 and P16 in 25 cases of teratomatous skin of ovarian mature cystic teratoma. Of 20 cases of squamous cell carcinoma P53 overexpression (positive rate of 55%) was detected in 11 cases, P16 overexpression (positive rate of 35%) in 7 cases. The positive rates of P53 and P16 expression in squamous cell carcinomas were significantly higher than that in the teratomatous skins (p< 0.001, p= 0.002). Conclusions: There was low risk of malignant transformation in teratomatous skin of ovarian mature cystic teratoma which can be explained by lower P53 and P16 expressionin teratomas than that in squamous cell carcinoma.
Keywords
Teratoma-malignant transformation; p53-p16; immunohistochemistry; squamous cell carcinoma;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ayhan A, Bukulmez O, Genc C, et al (2000). Mature cystic teratomas of the ovary: case series from one institution over 34 years. Eur J Obstet Gynecol Reprod Biol, 88,153-7.   DOI
2 Chang SD, Yen CF, Lo LM, et al (2011). Surgical intervention for maternal ovarian torsion in pregnancy. Taiwan J Obstet Gynecol, 50, 458-62.   DOI   ScienceOn
3 Climie AR, Heath LP (1968). Malignant degeneration of benign cystic teratomas of the ovary. Review of the literature and report of a chondrosarcoma and carcinoid tumor. Cancer, 22, 824-32.   DOI
4 Cabibi D, Martorana A, Cappello F, et al (2006). Carcinosarcoma of monoclonal origin arising in a dermoid cyst of ovary: a case report. BMC Cancer, 1, 46-47.
5 Dos Santos L, Mok E, Iasonos A, et al (2007). Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol, 105, 321-4.   DOI
6 Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759-67.   DOI
7 Guney N, Sayilgan T, Derin D, et al (2009). Primary carcinoid tumor arising in a mature cystic teratoma of the ovary: a case report. Eur J Gynaecol Oncol, 30, 223-5.
8 Fox H (1965). Bronchial carcinoma in an ovarian cystic teratoma (dermoid). J Clin Pathol, 1965, 18, 164-6.   DOI
9 Fujii T, Oguni S, Kikuchi M, et al (1995). p53 mutation in carcinomas arising in ovarian cystic teratomas. Pathol Int, 1995, 45, 649-54.   DOI
10 Hodges A, Smoller BR (2002). Immunohistochemical Comparison of P16 Expression in. Actinic Keratoses and Squamous Cell Carcinomas of the Skin. Mod Pathol, 15, 1121-5.   DOI
11 Hackethal A, Brueggmann D, Bohlmann MK, et al (2008). Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncology, 9, 1173-80.   DOI
12 Hirakawa T, Tsuneyoshi M, Enjoji M (1989). Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Am J Surg Pathol, 13, 397-405.   DOI
13 Hyun HS, Mun ST (2013). Primary malignant melanoma arising in a cystic teratoma. Obstet Gynecol Sci, 56, 201-4.   DOI
14 Kappes S, Milde-Langosch K, Kressin P, et al (1995). p53 mutations in ovarian tumors, detected by temperaturegradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer, 64, 52-9.   DOI
15 Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.   DOI
16 Ikota H, Kaneko K, Takahashi S, et al (2012). Malignant transformation of ovarian mature cystic teratoma with a predominant pulmonary type small cell carcinoma component. Pathol Int, 62, 276-80.   DOI
17 Klionsky BL, Nickens OJ, Amortegui AJ (1972). Squamous cell carcinoma in situ arising in adult cystic teratoma of the ovary. Arch. Pathol, 93, 161-3.
18 Li YM, Wan LY, Shen H (2011). Wood grain redyeing effects on quantitative analysis of immunohistochemical staining density. J Tropical Med, 11, 553-5.
19 Muramatsu T, Nishii T, Ohmori K, et al (2011). Mature cystic teratoma with malignant transformation to adenocarcinoma. Ann Thorac Surg, 91, 1971-3.   DOI
20 Oda Y, Sakamoto A, Saito T, et al (2000). Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol, 13, 994-1004.   DOI
21 Outwater EK, Siegelman ES, Hunt JL (2001). Ovarian teratomas, tumor types and imaging characteristics. Radiographics, 21, 475-490.   DOI   ScienceOn
22 Peterson WF (1957). Malignant degeneration of benign cystic teratomas of the overy: a collective review of the literature. Obstet Gynecol Surv, 12, 793-830.   DOI
23 Park JY, Kim DY, Kim JH, et al (2008). Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol, 141, 173-8.   DOI
24 Stamp GW, McConnell EM (1983). Malignancy arising in cystic ovarian teratomas. A report of 24 cases. Br J Obstet Gynaecol, 90, 671-5.   DOI
25 Palazzo JP, Monzon F, Burke M, et al (2000). Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol, 31, 698-704.   DOI
26 Ribeiro-Silva A, Chang D, Bisson FW, et al (2003). Clinicopathological and immunohistochemical features of a sebaceous carcinoma arising within a benign dermoid cyst of the ovary. Virchows Arch, 443, 574-8.   DOI
27 Rha SE, Byun JY, Jung SE, et al (2004). Atypical CT and MRI manifestations of mature ovarian cystic teratomas. AJR Am J Roentgenol, 183, 743-50.   DOI
28 Sumi T, Ishiko O, Yoshida H, et al (2001). Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med, 8, 495-8.
29 Sherr CJ (1993). Mammalian G1 cyclins. Cell, 73, 1059-65.
30 Takahashi H, Chaopotong P, Kajita S, et al (2012). Mixed angiosarcoma, clear cell adenocarcinoma and mature teratoma elements in an ovarian tumor: A case report and literature review. Pathol Int, 62, 538-42.   DOI
31 Ulbright TM (2005). Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol, 18, 61-79.   DOI
32 Weber A, Bellmann U, Bootz F (2002). INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch, 441, 133-142.   DOI
33 Yoshioka T, Tanaka T (1998). Immunohistochemical and molecular studies on malignant transformation in mature cystic teratoma of the ovary. J Obstet Gynaecol Res, 24, 83-90.   DOI